Released : November 07, 2019 07:00 RNS Number : 5671S MaxCyte, Inc. 07 November 2019 MaxCyte to Present at BIO-Europe 2019 Gaithersburg, Maryland - 07 November 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company , announces that President and
Released : November 01, 2019 13:04 RNS Number : 0228S MaxCyte, Inc. 01 November 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Result of AGM Gaithersburg, MD - 0 1 November 2019 : MaxCyte (LSE: MXCT, MXCR), the global cell-based therapies and life sciences company, announces that at
Released : October 24, 2019 07:00 RNS Number : 9395Q MaxCyte, Inc. 24 October 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Advances Phase I Clinical Trial of Lead CARMA™ mRNA-based Cell Therapy to Third Cohort of Patients MCY-M11 is being evaluated in relapsed/refractory
Released : October 23, 2019 07:01 RNS Number : 8257Q MaxCyte, Inc. 23 October 2019 MaxCyte Announces Presentations at 5th Annual Cell & Gene Therapy Congress Highlighting Unique Promise of Its Technology Gaithersburg, Maryland - 23 October 2019 - MaxCyte (LSE: MXCT, MXCS), the global
Released : October 08, 2019 07:00 RNS Number : 0594P MaxCyte, Inc. 08 October 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Notification of Annual General Meeting and Declaration of Audit Remuneration Gaithersburg, MD - 08 October 2019: MaxCyte (LSE: MXCT, MXCR), the global
Released : October 07, 2019 07:00 RNS Number : 9473O MaxCyte, Inc. 07 October 2019 Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines CAMBRIDGE, Mass. , and GAITHERSBURG, Md. , October 7, 2019 - Editas Medicine, Inc.
Released : September 18, 2019 07:00 RNS Number : 6880M MaxCyte, Inc. 18 September 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Results for the Six Months ended 30 June 2019 ¾ Strong commercial execution and financial performance with 21% year-over-year revenue growth ¾ Cell
Released : September 09, 2019 07:00 RNS Number : 5829L MaxCyte, Inc. 09 September 2019 MaxCyte Announces Presentation at ICLE 2019 Gaithersburg, Maryland - 9 September 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company , announces today that
Released : August 14, 2019 07:00 RNS Number : 9483I MaxCyte, Inc. 14 August 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Half Year Results Gaithersburg, Maryland - 14 August 2019: MaxCyte (LSE: MXCT, MXCS), the global clinical-stage cell-based therapies and life
